Skip to Content

Bexarotene Pregnancy and Breastfeeding Warnings

Bexarotene is also known as: Targretin

Bexarotene Pregnancy Warnings

This drug is a retinoid, a drug class associated with birth defects in humans. Additionally, animal studies have revealed evidence of developmental mortality, teratogenicity (e.g., cleft palate, incomplete ossification, depressed eye bulge/microphthalmia, small ears), testicular degeneration, and reversible aspermatogenesis. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

UK: Use is contraindicated during pregnancy and in women of childbearing potential without effective birth control measures. US: Use is contraindicated during pregnancy. US FDA pregnancy category: Not Assigned Comments: -Negative pregnancy tests (e.g., serum beta-human chorionic gonadotropin [beta-HCG]) with sensitivity of at least 50 mIU/L should be obtained within one week prior to therapy and at monthly intervals during treatment. -Female patients of reproductive potential should use effective contraception for one month prior to therapy initiation, during therapy, and for at least one month following treatment discontinuation. -Two reliable forms of contraception should be used simultaneously; one form should be non-hormonal as this drug may reduce the efficacy of oral and other systemic hormonal contraceptives. -Male patients should use condoms during treatment and for at least one month after the last dose if they have sexual partners who are pregnant or of childbearing potential.

See references

Bexarotene Breastfeeding Warnings

UK: Breastfeeding is contraindicated during treatment. US: Breastfeeding should be discontinued during treatment. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant and on milk production are unknown.

See references

References for pregnancy information

  1. "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.

References for breastfeeding information

  1. "Product Information. Targretin (bexarotene)" Ligand Pharmaceuticals, San Diego, CA.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.